US rheumatologists' beliefs and knowledge about biosimilars: a survey.

ABSTRACT:

Objectives

We sought to evaluate perceptions of biosimilar products among US rheumatologists who prescribe TNF-α inhibitors, given that 10 TNF-α inhibitor biosimilars and two rituximab biosimilars have Food and Drug Administration (FDA) approval.

Methods

A 19-question self-administered online survey was conducted from 6 May to 1 June 2019, and fielded by WebMD, LLC. Rheumatologists (n = 9050) who were members of Medscape.com and its partner panels were invited to participate. Likert and other rating scales were used to collect responses, which were summarized descriptively.

Results

Responses were obtained from 320 board-certified US rheumatologists, 85% of whom were fellows of the ACR. Nearly all respondents were familiar with the FDA definition of a biosimilar produc

SUBMITTER: Gibofsky A 

PROVIDER: S-EPMC7850535 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature